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OBJECTIVE — Low levels of fetuin-A, a systemic calciﬁcation inhibitor, are linked to mor-
tality in patients on dialysis. In contrast, elevated fetuin-A is associated with cardiovascular
events in non-renal patients. We investigated fetuin-A in patients with type 2 diabetes and
peripheral arterial disease (PAD).
RESEARCHDESIGNANDMETHODS — Westudiedfetuin-Ain76patientswithPAD
and normal glucose metabolism (NGM-PAD) and in 129 patients with PAD and type 2 diabetes
(type 2 diabetes–PAD). Additionally, 40 patients with diabetes without any complications (type
2 diabetes–non-PAD) were examined.
RESULTS — Type 2 diabetes–PAD subjects (399  155 g/ml) had signiﬁcantly higher
fetuin-A levels than type 2 diabetes–non-PAD subjects (247  42; P  0.001). In NGM-PAD
subjects (376  144), fetuin-A was signiﬁcantly higher than in type 2 diabetes–non-PAD sub-
jects (P  0.001). Type 2 diabetes–PAD patients with mediasclerosis had lower fetuin-A than
subjects without (P  0.03). Regression analysis in type 2 diabetes–PAD subjects revealed that
glycated A1C (P  0.001) and mediasclerosis (P  0.004) were the strongest predictors of
fetuin-A.Multivariateregressionrevealedthata1-SDincreaseinfetuin-Awasassociatedwithan
odds ratio (OR) of 2.1 (95% CI 1.1–3.3; P  0.001) for the prevalence of PAD and an OR of 1.4
(1.0–1.7, P  0.039) for the prevalence of myocardial infarction.
CONCLUSIONS — Incontrasttopreviousﬁndings,fetuin-Awashigherintype2diabetes–
PADpatientsthanintype2diabetes–non-PADpatients.InNGM-PADpatients,fetuin-Awasalso
higher than in type 2 diabetes–non-PAD patients. In type 2 diabetes–PAD patients, fetuin-A was
inversely associated with mediasclerosis—the calciﬁcation process pathognomonic for diabetic
PAD. This association persisted in multivariate regression, which is in line with the calciﬁcation
inhibition in coronary heart or renal disease.
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P
atients suffering from type 2 diabe-
tes and peripheral artery disease
(PAD)(type2diabetes–PAD)havea
ﬁve times higher risk for cardiovascular
mortality than patients with one disease
alone(1–3).Furthermore,theriskoflow-
er-extremity amputation is higher than in
patients without diabetes (3).
Fetuin-A, also known as 2-Schmid
Heremans glycoprotein (ASHG), is a po-
tent systemic calciﬁcation inhibitor (4).
Fetuin-A knockout mice develop severe
calciﬁcation of various organs (4). In a
cross-sectional study, low levels of fe-
tuin-A were associated with cardiovascu-
lar mortality in patients on dialysis (5). In
addition, low fetuin-A has been linked to
vascular calciﬁcation (6) and ﬂow-
limiting aortic stenosis (7).
Fetuin-Ainteractswiththeinsulinre-
ceptor tyrosine kinase and induces insu-
linresistanceinrodents(8,9).Stefanetal.
(10) demonstrated in a prospective case-
cohort study that elevated fetuin-A is an
independentriskfactorfordevelopingdi-
abetes.Contrariwisetorenal(dialysis)pa-
tients, several studies showed that high
levels of fetuin-A were associated with
atherosclerosis and its manifestations in
non-renal patients (11–13). Likewise,
high levels of fetuin-A were linked to
myocardial infarction and ischemic
stroke (12). This possible involvement of
fetuin-A in the pathogenesis of cardiovas-
cular disease has been conﬁrmed by a re-
cent trans-European cohort study with
2,520 patients (13). Thus, it seems that
high levels of fetuin-A are associated with
atherosclerosis and its manifestations in
non-renal patients.
In contrast to the latter ﬁndings, a re-
cent article (14) suggested that fetuin-A
levels in a non-dialysis condition are
lower in type 2 diabetes–PAD patients
(n  38) than in patients with diabetes
alone.
However, the role of fetuin-A and its
involvement in atherosclerosis seems to
be very complex and yet not understood.
Thesituationisevenmorecomplexinpa-
tients with type 2 diabetes–PAD, who
generally suffer from advanced/systemic
atherosclerosis (1–3,15). In those high-
risk patients, up to 30% show mediascle-
rosis (2,15). The aim of this study was to
investigatefetuin-Alevelsinpatientswith
type 2 diabetes with or without PAD in
comparison with PAD patients with
diabetes.
RESEARCH DESIGN AND
METHODS— The study was ap-
proved by the institutional ethics com-
mittee and complies with the Declaration
of Helsinki and Good Clinical Practice.
After giving written informed consent,
patients were enlisted at the Angiology
Outpatients’ Division, Department of
Medicine II, Medical University and Gen-
eral Hospital of Vienna, and the Diabetes
Outpatients’ Division, Department of
Medicine I, Rudolfstiftung Hospital,
Vienna.
In this cross-sectional study, we
present 205 patients with PAD. Blood
samples were collected after an overnight
fast (12 h) from the cubital vein, immedi-
ately centrifuged, and deep-frozen at
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lines(16),patientswereclassiﬁedaccord-
ing to a standardized oral glucose
tolerance test as overt type 2 diabetes or
normal glucose metabolism (NGM).
NGM was deﬁned as having fasting
plasma glucose 5.6 mmol/l and a 2-h
postload plasma glucose 7.8 mmol/l.
The NGM group did not contain patients,
withimpairedfastingglucoseorimpaired
glucose tolerance.
As manifestations of atherosclerosis,
we deﬁned PAD, upper-extremity arterial
disease, renal arterial disease, thoracic or
abdominal aortic disease, coronary heart
disease, cerebrovascular disease (CVD),
and associated events such as myocardial
infarction or stroke.
PAD was classiﬁed after Fontaine by
the self-reported pain-free walking dis-
tance. Blood pressures to calculate ankle
brachial index (ABI) and toe brachial in-
dex (TBI) were measured by trained per-
sonnel(2,15).AsymptomaticPAD(stageI
Fontaine) was deﬁned by ABI 0.9
and/or TBI 0.7. Digital oscillography
was performed. In the case of noncompa-
rablewaveforms,stressoscillograms(17)
were performed to detect occult stenosis.
If noncompressible arteries or an ABI
1.4andtypicalwaveformdeviationsby
oscillography were observed, patients
were diagnosed as having Mo ¨nckeberg’s
mediasclerosis (17). Estimated glomeru-
lar ﬁltration rate (eGFR) (18) was calcu-
lated. Exclusion criteria were PAD
Fontaine stage III or IV, type 1 diabetes,
serum creatinine 3 mg/dl, dialysis, con-
nective tissue disease, critical illness
within the last 6 months, hormone re-
placement therapy, and known cancer.
As reference cohorts, we enrolled 40
patientswithdiabeteswithoutanymicro-
or macrovascular complications (type 2
diabetes–non-PAD) (Rudolfstiftung Hos-
pital). To ensure that the type 2 diabetes–
non-PAD group has no clinical evidence
ofvascularcomplications,inclusioncrite-
ria were as following: duration of type 2
diabetes 5 years, at maximum one oral
antidiabetic drug, no insulin intake, A1C
8%, creatinine 1.4 and no albumin-
uria (albuminuria 30 mg/day/24-h
urine), ABI 0.90, and/or TBI 0.70. In
addition, the patients underwent a stress
ergometer test, and a fundal inspection of
the eye was performed.
Serum concentrations of fetuin-A
wereassessedbyacommerciallyavailable
ELISA (BioVendor Laboratory Medicine,
Modrice, Czech Republic). Measured in-
tra-assay and interassay variability coefﬁ-
cients were 10.2 and 10.0%, respectively.
All data are presented as means  SD
ormedians(25th,75thpercentile).Statis-
tical analyses were performed using SPSS
15.0 (SPSS, Chicago, IL) and included
an independent-sample Student t test, 
2
test, ANOVA, Kruskal-Wallis, Mann-
Whitney U test, and univariate and
multivariate, linear, logistic, and
multi-nominal regression analysis as ap-
propriate. Confounding in multivariate
analysiswasidentiﬁedbyachangein	of
10% (19). A two-sided  level 0.05
wasconsideredstatisticallysigniﬁcant.To
investigate differences of fetuin-A in dia-
betes and PAD independent of age and
sex, a cutoff of 69 years of age was used to
obtainpatientgroupsthatdidnotdifferin
age and sex.
RESULTS
Baseline characteristics
Baseline characteristics are presented in
Table 1. Patient groups differed for age,
BMI, eGFR, lipids, and A1C.Thus, age
and sex matching was applied. However,
in the matched groups, differences in lip-
ids, BMI, and A1C persisted (Table 2).
Fetuin-A levels
Fetuin-AindifferentgroupsisshowninFig.
1: The highest fetuin-A concentration was
found in type 2 diabetes–PAD subjects
(399  155 g/ml) followed by patients
with PAD and normal glucose metabolism
(NGM-PAD) (376  144 g/ml). Further-
more, fetuin-A levels in type 2 diabetes–
PAD subjects were higher than in type 2
diabetes–non-PAD subjects (247  42 g/
ml; P0.001). In patients with PAD alone
(NGM-PAD), fetuin-A was higher com-
pared with patients with type 2 diabetes–
Table 1—Baseline characteristics of different study groups
Type 2
diabetes–non-PAD
(group 1)
NGM-PAD
(group 2)
Type 2
diabetes-PAD
(group 3)
P
(all groups)
P
(1 vs. 2)
P
(1 vs. 3)
P
(2 vs. 3)
n 40 76 129
Age (years) 61.1  10.0 68.3  10.5 70.8  9.2 0.001* 0.001* 0.001* 0.081
Male sex (%) 21 (53) 42 (55) 93 (72) 0.015* 0.776 0.021* 0.014*
Systolic blood pressure (mmHg) 145  22 139  20 145  23 0.115 0.146 0.894 0.044*
Diastolic blood pressure (mmHg) 90  11 78  14 78  11 0.001* 0.001* 0.004* 0.970
BMI (kg/m
2) 31.9  5.4 25.7  3.6 28.6  4.5 0.001* 0.001* 0.001* 0.001*
eGFR (ml/min/1.73 m
2) 88.0  40.5 71.8  16.5 66.4  19.1 0.001* 0.032* 0.005* 0.043*
Triglyceride (mmol/l) 2.2  1.4 1.8  0.9 2.0  1.2 0.101 0.084 0.416 0.087
HDL (mmol/l) 1.3  0.4 1.5  0.3 1.3  0.3 0.001* 0.158 0.240 0.001*
Total cholesterol (mmol/l) 5.1  0.9 5.3  1.2 4.7  1.2 0.002* 0.338 0.108 0.001*
LDL (mmol/l) 2.8  0.8 3.1  1.0 2.6  1.0 0.001* 0.196 0.182 0.001*
Bilirubin (mol/l) 11.3  6.8 10.9  3.6 11.6  4.8 0.738 0.828 0.851 0.381
Alkaline phosphatase (U/l) 82.3  29.2 79.2  23.8 85.7  49.3 0.542 0.560 0.711 0.29
Aspartate transaminase (U/l) 27.1  8.9 25.2  6.2 25.7  9.3 0.566 0.283 0.434 0.686
Alanine transaminase (U/l) 27.6  12.5 24.1  10.1 28.0  12.8 0.079 0.129 0.880 0.026

-Glutamyl transferase (U/l) 54.5  41.7 41.2  34.8 52.7  100.4 0.554 0.089 0.920 0.341
C-reactive protein (mg/l) NA 2.6 (1.5, 4.4) 3.2 (1.4, 6.1) — — — 0.092
A1C (relative %) 7.7  1.3 5.7  0.4 6.9  1.1 0.001* 0.001* 0.001* 0.001*
Data are means  SD, median (25, 75 percentile), or n (%). *P  0.05 is considered statistical signiﬁcant. NA, not applicable.
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fetuin-A levels in the age- and sex-matched
subjects persisted (Table 2).
To investigate a possible association
of fetuin-A with atherosclerotic burden,
we deﬁned subgroups of type 2 diabetes–
PAD: patients who had atherosclerosis
beside PAD such as coronary heart dis-
ease, CVD, stroke, or myocardial infarc-
tion (n  62) and patients with PAD as
onlymanifestationofatherosclerosis(n
67); fetuin-A was not different (408 
171 vs. 391  139 g/ml; P  0.54). In
addition, in all patients (n  245), the
association of number of sites of athero-
sclerosis and fetuin-A levels were signiﬁ-
cant in univariate regression (	0.336,
P  0.001). In the matched subjects (Ta-
ble 2), the association strengthened (	
0.424, P  0.001).
Because fetuin-A is a calciﬁcation in-
hibitor, we analyzed whether fetuin-A is
associated with mediasclerosis in type 2
diabetes–PAD. Type 2 diabetes–PAD pa-
tients with mediasclerosis (n  49) had
lower fetuin-A levels than patients with-
out (n  53) (370  135 vs. 434  157
g/ml,P0.03),butstillhadhigherlev-
els than patients with type 2 diabetes–
non-PAD (P  0.001).
Tertiles of fetuin-A
The patients were divided into tertiles to
investigate associations of quantitative
and qualitative parameters with high fe-
tuin-A levels (Table 3). Patients in the
lowest and highest tertile of fetuin-A dif-
fered for coronary heart disease (P 
0.006) and myocardial infarction (P 
0.020).
As expected from the baseline char-
acteristics (Table 1) and as shown in
Fig. 1, fetuin-A in tertiles was also asso-
ciatedwiththeassignedpatientcohorts:
the lowest-risk group, type 2 diabetes–
non-PAD, was 40% of the patients
in the ﬁrst tertile of fetuin-A (P 
0.001).
To date, a direct association of fe-
tuin-A levels with clinical stages of PAD is
not known. We found a signiﬁcant in-
crease of more pronounced stages of PAD
in the highest versus the lowest or the in-
termediate tertile of fetuin-A levels (P 
0.001, Table 3).
Figure1—Thelevelsoffetuin-Ainmicrogramspermilliliterinallthreepatientgroups.T2D,type
2 diabetes. In-between group differences were analyzed by an unpaired Student t test.
Table 2—Baseline characteristics of age- and sex-matched patients in the different study groups
Type 2
diabetes–non-PAD
(group 1)
NGM-PAD
(group 2)
Type 2
diabetes–PAD
(group 3)
P
(all groups)
P
(1 vs. 2)
P
(1 vs. 3)
P
(2 vs. 3)
n 40 44 55
Age (years) 61.1  10.0 61.1  6.6 62.2  4.9 0.685 0.995 0.525 0.367
Male sex (%) 21 (53) 28 (64) 38 (69) 0.253 0.301 0.100 0.567
Systolic blood pressure (mmHg) 145  22 139  21 141  17 0.440 0.252 0.351 0.696
Diastolic blood pressure (mmHg) 90  11 82  14 78  11 0.001* 0.024* 0.001* 0.124
BMI (kg/m
2) 31.9  5.4 26.1  3.4 29.6  4.7 0.001* 0.001* 0.031* 0.001*
eGFR (ml/min/1.73 m
2) 88.0  40.5 76.9  15.1 74.6  19.2 0.050 0.141 0.082 0.525
Triglyceride (mmol/l) 2.2  1.4 1.8  1.0 2.3  1.2 0.182 0.155 0.922 0.070
HDL (mmol/l) 1.3  0.4 1.4  0.3 1.2  0.3 0.002* 0.309 0.064 0.001*
Total cholesterol (mmol/l) 5.1  0.9 5.3  1.4 4.7  1.3 0.033* 0.382 0.112 0.018*
LDL (mmol/l) 2.8  0.8 3.1  1.2 2.5  1.1 0.026* 0.260 0.167 0.012*
Bilirubin (mol/l) 11.3  6.8 10.7  3.4 11.0  3.6 0.838 0.635 0.829 0.636
Alkaline phosphatase (U/l) 82.3  29.2 78.6  23.6 90.7  69.7 0.459 0.534 0.515 0.272
Aspartate transaminase (U/l) 27.1  8.9 26.3  6.0 25.4  11.2 0.683 0.689 0.456 0.597
Alanine transaminase (U/l) 27.6  12.5 27.0  11.4 30.2  14.2 0.417 0.834 0.376 0.222

-Glutamyl transferase (U/l) 54.5  41.7 51.6  40.8 64.8  145.7 0.787 0.765 0.693 0.563
C-reactive protein (mg/l) NA 2.7 (1.5, 4.5) 3.5 (1.6, 7.0) — — — 0.095
A1C (relative %) 7.7  1.3 5.7  0.4 7.2  1.2 0.001* 0.001* 0.034* 0.001*
Fetuin-A (g/ml) 247.19  41.82 356.45  125.59 411.19  163.02 0.001* 0.001* 0.001* 0.070
Data are means  SD, medians (25, 75 percentile), or n (%). *P  0.05 is considered statistically signiﬁcant. NA, not applicable.
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Univariateregressionforfetuin-Alevelsin
all patients included all available quanti-
tativeparameters(Table1):onlyage(	
0.115,P0.073)showedatrendtoward
signiﬁcant association. After reduction of
confounding (19), multivariate regres-
sion did not change the prediction of fe-
tuin-A. Next, age- and sex-matched
subjects(Table2)(ourgroupsdifferedfor
age) were introduced to multivariate re-
gression: we failed to obtain any signiﬁ-
cant model for the explanation of
fetuin-A.
InpatientswithPAD(NGM-PADand
type 2 diabetes–PAD), two variables were
associated with fetuin-A in univariate
fashion:A1C(	0.196,P0.005)and
pack-yearsofsmoking(	0.166,P
0.033).Bothvariablesremainedindepen-
dent from each other predictive for fe-
tuin-A in multivariate fashion.
Multivariate regression in type 2 dia-
betes–PADrevealedthatthetwovariables
that were associated with fetuin-A levels
in univariate fashion remained predictive
in multivariate analysis: A1C (	0.348,
P  0.001) and mediasclerosis (	
0.281, P  0.004) were the strongest
predictors for fetuin-A in type 2
diabetes–PAD.
Prediction of PAD
Because the prevalence of PAD was asso-
ciated with tertiles of fetuin-A, we tested
whether linear fetuin-A predicted PAD in
a univariate or multivariate fashion. In a
univariate fashion, each 10 g/ml in-
crease in fetuin-A resulted in a 13% in-
crease in odds ratio (OR) (95% CI 8.0–
18, P  0.001) having advanced PAD
(increasefromnoPADoverPADFontaine
stage I to PAD Fontaine stage II). A mul-
tivariate model adjusted for age, eGFR,
LDL, HDL, A1C, BMI, and sex revealed
that the predictive power of fetuin-A im-
provedby30%:each10g/mlincreaseof
fetuin-A now resulted in a 17% increase
in OR (95% CI 9–25, P  0.001). In this
model, apart from fetuin-A, age was iden-
tiﬁedasasigniﬁcantpositivepredictor:an
increase of age in 1 unit in the latter vari-
ables resulted in a 9% likelihood of ad-
vancement of PAD (95% CI 1–17, P 
0.031). To compare the power of those
factors, OR per 1-SD change was calcu-
lated: 1-SD change of fetuin-A resulted in
an OR of 3.5 (95% CI 2.3–4.7, P 
0.001); 1-SD change in age resulted in an
OR of 1.9 for advancement of PAD (95%
CI 1.1–2.8, P  0.001).
Because Eraso et al. (14) showed an
unadjusted and adjusted OR of 1.6 per
decrease of 1 SD fetuin-A for the preva-
lence(noversusyes)ofPADintheirstudy
cohort, we applied a similar model in our
cohort. Unadjusted, the OR per increase
of1SDfetuin-AfortheprevalenceofPAD
Table 3—Baseline characteristics of patients in fetuin-A tertiles
Tertile 1 Tertile 2 Tertile 3
P
(all three
groups)
P
(1 vs. 3)
Fetuin-A (g/ml) 286.69 286.70–389.97 389.98
n 82 82 81
Age (years) 66.7  11.2 69.5  9.6 69.2  9.9 0.161 0.135
Male sex (%) 53 (65) 51 (62) 52 (64) 0.942 0.954
Systolic blood pressure (mmHg) 140  21 147  23 142  22 0.146 0.583
Diastolic blood pressure (mmHg) 81  13 79  11 80  14 0.512 0.578
BMI (kg/m
2) 29.0  5.0 27.9  5.1 27.8  4.3 0.190 0.096
eGFR (ml/min/1.73 m
2) 77.1  30.9 67.4  21.2 69.4  17.5 0.028* 0.063
Triglyceride (mmol/l) 1.9  1.2 2.0  1.2 2.1  1.0 0.474 0.217
HDL (mmol/l) 1.4  0.4 1.3  0.3 1.3  0.3 0.571 0.316
Total cholesterol (mmol/l) 5.1  1.5 4.8  1.0 5.0  1.1 0.460 0.777
LDL (mmol/l) 2.8  1.2 2.6  0.9 2.8  1.0 0.391 0.903
Bilirubin (mol/l) 11.5  5.4 11.4  4.6 11.1  3.5 0.805 0.542
Alkaline phosphatase (U/l) 88.8  56.2 81.7  35.0 79.4  23.9 0.325 0.175
Aspartate transaminase (U/l) 26.9  9.1 25.3  9.4 25.0  6.1 0.320 0.132
Alanine transaminase (U/l) 27.0  12.8 26.0  11.8 27.0  11.6 0.844 0.979

-Glutamyl transferase (U/l) 62.7  126.9 44.6  39.3 41.5  36.1 0.193 0.153
C-reactive protein (mg/l) 2.9 (1.0, 5.7) 2.3 (1.0, 4.5) 3.0 (1.6, 5.6) 0.256 0.888
A1C (relative %) 6.9  1.3 6.5  1.2 6.7  1.1 0.082 0.422
Coronary heart disease 13 (16) 25 (31) 28 (35) 0.018* 0.006*
Myocardial infarction 6 (7) 16 (20) 16 (20) 0.043* 0.020*
Carotid artery disease 10 (12) 12 (15) 14 (17) 0.656 0.359
Stroke 6 (7) 8 (10) 5 (6) 0.682 0.771
PAD
Non-PAD 35 (43) 4 (5) 1 (1)
Stage I 21 (25) 38 (46) 34 (42) 0.001* 0.001*
Stage II 26 (32) 40 (49) 46 (57)
Group
Type 2 diabetes–non-PAD 35 (43) 4 (5) 1 (1)
NGM-PAD 28 (34) 46 (56) 55 (68) 0.001* 0.001*
Type 2 diabetes–PAD 19 (23) 32 (39) 25 (31)
Data are means  SD, medians (25, 75 percentile), or n (%). *P  0.05 is considered statistically signiﬁcant.
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Adjustment for age, sex, eGFR, HDL,
LDL, triglycerides, total cholesterol, A1C,
systolic blood pressure, bilirubin, alka-
line phosphatase, aspartate transaminase,
alanine transaminase, and 
-glutamyl
transferase strengthened the association:
OR per 1-SD increase of fetuin: 3.8 (95%
CI 2.5–5.0).
CONCLUSIONS — In this study, we
demonstrated that patients with type 2
diabetes who additionally suffer from
PAD have signiﬁcantly higher fetuin-A
levels than patients with diabetes but
without any atherosclerotic burden.
Our data are in opposition to the re-
sults from Eraso et al. (14), who assumed
that patients with type 2 diabetes and
PAD have lower plasma concentrations of
fetuin-A than patients with type 2 diabe-
tes alone. In the latter study, 738 patients
with type 2 diabetes but without clinical
evidence of cardiovascular disease were
enrolled. From these study participants,
only 5.1% (n  38) had PAD, deﬁned by
an ABI 0.9. Although PAD patients
show the highest co-burden of manifesta-
tions of atherosclerosis (15), which is
evenhigherinpatientswithPADandtype
2diabetes(1–3,15),the38patientsinthe
latter article did not show any other man-
ifestationofatherosclerosisandmustthus
be regarded as highly selected and not
representative (20).
In contrast to Eraso et al. (14), a de-
crease of fetuin-A did not result in an in-
creaseofPAD.Inourstudy,anincreaseof
1 SD fetuin-A resulted in an increase of
PAD: OR 2.9 (95% CI 2.2–3.7, P 
0.001). Adjustment for multiple variables
did not attenuate this association, but in-
creased its strength: OR 3.8 (95% CI 2.5–
5.0, P  0.001).
Recent studies showed a strong asso-
ciationbetweenfetuin-Alevelsandevents
of CVD (11,12). Weikert et al. (12) ob-
tained a signiﬁcantly increased risk for
myocardial infarction (relative risk [RR]
3.3) and ischemic stroke (RR 3.8) for in-
dividuals in the highest compared with
the lowest quintile of fetuin-A in a model
adjustedforcardiovascularriskfactorsin-
cludingage,sex,diabetes,BMI,HDL,and
high sensitive C-reactive protein. The
change per category of fetuin-A quintiles
inthestudyofWeikertetal.(12)ofanRR
of 1.7 for myocardial infarction was sim-
ilar to our OR of 1.6 per categorical fe-
tuin-A change (95 CI 1.1–2.5, P 
0.030). In addition, cases with coronary
heart disease in the fetuin-A tertiles in-
creasedfrom13(16%),over25(31%),to
28 (35%) (P  0.018, Table 3). The ﬁnd-
ings by Fisher et al. (13) suggest the sus-
picion of a causal relationship of fetuin-A
levels, ASHG (fetuin-A) gene polymor-
phisms, and atherosclerotic events. Like-
wise, the ASHG rs4917 C 3 T
polymorphism showed a signiﬁcant asso-
ciation with myocardial infarction (ad-
justed hazard rate 1.34, 95% CI 1.05–
1.70, P  0.02), although it explained
only 21.2% of the phenotypic variance of
fetuin-Aplasmalevelsindependentofpo-
tential confounding factors. Results of the
latter studies (11–13) nourish the theory
that fetuin-A may play a causal role in the
pathophysiology of atherosclerosis lead-
ingtoCVD,notonlyinrodentsbutalsoin
humans. Prevalence of myocardial infarc-
tion was limited to 16% in our cross-
sectional study. Nevertheless, the power
was sufﬁcient to obtain signiﬁcant associ-
ations: a categorical change in fetuin-A
levels resulted in an OR of 1.7 (95% CI
1.0–2.7,P0.041)aftermultivariatead-
justment for age, LDL, eGFR, A1C, and
sex. Our results underline the ﬁndings
that higher fetuin-A levels are associated
with atherosclerosis (11–13,21), al-
though due to the cross-sectional design
of our study, we cannot answer yet
whether fetuin-A has predictive power in
patients with type 2 diabetes with and
without PAD.
Stefan et al. (10) have shown that fe-
tuin-A levels predict type 2 diabetes. In
our cohort, patients with advanced ath-
erosclerosis (type 2 diabetes–PAD and
NGM-PAD) had higher levels of fetuin-A
regardless of diabetes status, suggesting
that fetuin-A might be independently (of
diabetes) associated with CVD.
In agreement with Ix et al. (22), we
found that higher fetuin-A was associated
with increased odds for the metabolic
syndrome (MetS) in our patients with
PAD. An association of features of MetS
and fetuin-A was also described by
Reinehr and Roth (23) in obese children.
In our patients with PAD, the association
of fetuin-A and MetS was restricted to the
National Cholesterol Education Program
(NCEP) Adult Treatment Panel (ATP) 3
deﬁnition and did not result in signiﬁ-
cance in the World Health Organization
and International Diabetes Federation
classiﬁcation of MetS. A 1-SD change in
fetuin-A resulted in an OR for MetS of 1.3
(95% CI 1–1.6, P  0.044). Vice versa,
only MetS deﬁned by NCEP ATP-3 pre-
dicted fetuin-A at a level of signiﬁcance
(	0.142, P  0.042). In summary,
high fetuin-A levels seem to be associated
with MetS, insulin resistance, diabetes,
myocardial infarction, and PAD in pa-
tients with and without diabetes.
In contrast, low levels of fetuin-A
have been associated with CVD in pa-
tients on dialysis (5). In the last years,
many biological parameters in humans
have been shown to follow not a simple
linear association, but a U-shaped rela-
tionship,e.g.,BMI,hemoglobin,andA1C
(the latter in diabetes). Ix et al. (23) sug-
gestedaU-shapedrelationshipalsoforfe-
tuin-AvalueswithCVD.Theyconsidered
either high or low levels of fetuin-A to
predict cardiovascular events. High levels
by associations with MetS and athero-
genic lipids result in CVD; low levels by
associations with vascular calciﬁcation
also result in CVD.
Mehrotra et al. (24) and Mori et al.
(25) showed a positive association be-
tween fetuin-A and coronary artery calci-
ﬁcation and arterial stiffness in subjects
without dialysis. Because those studies
were cross-sectional, it is not impossible
that fetuin-A had detrimental effects on
vasculature or that fetuin-A is upregu-
lated to protect against calciﬁcation pro-
cesses in atherosclerosis. Low fetuin-A
levels were associated with mitral annular
calciﬁcation and aortic stenosis in pa-
tients with coronary heart disease (6,7).
Therefore, it is possible that fetuin-A is
upregulated to protect against calciﬁca-
tion but deteriorates atherosclerosis (6).
Nevertheless, in our study, patients
withmediaarterysclerosisshowedsignif-
icantly lower levels of fetuin-A. Thus, our
study is in line with the calciﬁcation inhi-
bition competence of fetuin-A, but levels
of fetuin-A were still signiﬁcantly higher
compared with patients with diabetes
alone (type 2 diabetes–non-PAD).
Supporting the idea that low fetuin-A
causes vascular calciﬁcation, we observed
in patients with PAD (NGM-PAD and
type2diabetes–PAD)thatthetotalsmok-
ing dosage showed a negative association
(	 0.166, P  0.033) with fetuin-A.
The observation that long term smoking
results in severe clinical vessel calciﬁca-
tion is not understood and is now the fo-
cus of scientiﬁc interest. Because our
study is cross-sectional, we cannot state if
smoking decreases fetuin-A levels and
thus affects vascular calciﬁcation.
In summary, we demonstrate that fe-
tuin-A levels are not decreased in patients
with diabetes and atherosclerosis, but are
Fetuin-A and diabetes/PAD
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dial infarction are associated with higher
fetuin-A values. In addition, we support
thehypothesisthatlowfetuin-Amightre-
sult in vascular calciﬁcation. Finally, we
are ﬁrst to report that low fetuin-A is as-
sociated with mediasclerosis in patients
with diabetes and PAD.
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